About AtriCure
Current AtriCure investor news releases from the official investor relations feed.
Official Investor Relations Feed
10 current records
MASON, Ohio --(BUSINESS WIRE)--Jul. 27, 2026-- AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating
Read the full releaseSecond Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year Second Quarter 2026 profitability strengthened, with net income of $9.0 million and adjusted EBITDA of $27.3 million Second Quarter 2026 cash generation of $21.6 million MASON, Ohio --(BUSINESS WIRE)--Jul.
Read the full releaseMASON, Ohio --(BUSINESS WIRE)--Jul. 2, 2026-- AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter
Read the full releaseMASON, Ohio --(BUSINESS WIRE)--May 27, 2026-- AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating
Read the full releaseFirst Quarter 2026 worldwide revenue of $141.2 million, an increase of 14.3% year over year First Quarter 2026 profitability improved, with net income of $0.1 million and adjusted EBITDA of $17.1 million U.S. revenue growth accelerated to 14.9%, driven by AtriClip FLEX-Mini ®, cryoSPHERE ® MAX ™,
Read the full releaseMASON, Ohio --(BUSINESS WIRE)--Apr. 28, 2026-- AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating
Read the full releaseMASON, Ohio --(BUSINESS WIRE)--Apr. 14, 2026-- AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter
Read the full releaseMASON, Ohio --(BUSINESS WIRE)--Feb. 24, 2026-- AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating
Read the full releaseFourth Quarter 2025 worldwide revenue of $140.5 million – an increase of 13.1% year over year Fourth Quarter 2025 net income of $1.8 million and positive adjusted EBITDA of $19.9 million Full Year 2025 worldwide revenue of $534.5 million – an increase of 14.9% year over year Full Year 2025 net loss
Read the full releaseMASON, Ohio --(BUSINESS WIRE)--Jan. 27, 2026-- AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter
Read the full release